-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

Benzinga·10/07/2026 13:33:33
Listen to the news
Barclays analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $157 to $156.